Poolbeg Pharma Highlights POLB 001 Interest and Financial Discipline

September 18, 2024 11:24 AM MSK | By Team Kalkine Media
 Poolbeg Pharma Highlights POLB 001 Interest and Financial Discipline
Image source: Shutterstock

Poolbeg Pharma PLC (LSE:POLB) has outlined significant advancements for its lead drug, POLB 001, in its recent first-half results report, which also noted a cash balance of £10.1 million as of June 30.

POLB 001 is being developed as the first approved therapy that provides both prevention and treatment options for cytokine storms in patients undergoing cancer immunotherapy. Independent research suggests a potential market opportunity of approximately $10 billion. During this reporting period, Poolbeg strengthened its patent and intellectual property portfolio, receiving a grant from the US Patent Office for an Immunomodulator II patent, which covers a class of drugs, including POLB 001, for the treatment or prevention of hypercytokinemia across various disease indications.

The company's engagement with potential partners regarding POLB 001 has generated interest, as noted by Chief Executive Jeremy Skillington. The independent confirmation of the drug's market potential has enhanced its attractiveness to pharmaceutical partners. Skillington emphasized that as companies seek to improve the safety and market reach of their cancer immunotherapies, POLB 001 is positioned to deliver value while addressing critical unmet medical needs.

Additionally, Poolbeg's strategy increasingly focuses on rare and orphan diseases, highlighted by a recent exclusive option agreement for tPTX, a novel topical treatment for oral ulcers in patients with Behçet's Disease, which has received US regulatory fast-track and orphan drug designations.

Upcoming developments include the initiation of a clinical trial for an orally-delivered GLP-1 receptor agonist aimed at the obesity market, projected to commence towards the end of 2024. Poolbeg noted the limited availability of oral GLP-1 receptor options, with its program aiming to enhance bioavailability and patient convenience through innovative delivery systems.

The reported cash balance is attributed to prudent financial management during a period of operational loss, with expenditures primarily on research and development and administrative costs, offset by tax rebates and other income. This financial stewardship positions Poolbeg well for its upcoming initiatives and strategic objectives.

 

 


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (Kalkine Media, we or us) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalised advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Sponsored Articles


We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.